On World Cancer Day (today, February 4), CuraCell highlights its efforts to advance innovative T-cell therapies for hard-to-treat solid tumors, including immunologically “cold” cancers that have historically resisted current immunotherapies. Through proprietary platforms and strategic collaborations, the company is working to extend the reach of cellular therapies, improve patient outcomes, and generate clinically meaningful evidence in oncology. Discover Pharma posed a couple of questions to CuraCell.

What recent research, therapy, or patient support initiatives from your company are making a real impact in oncology?

CuraCell’s recent research and development efforts in oncology are focused on advancing innovative T-cell therapies that address some of the most urgent unmet needs in cancer treatment.

A major initiative making a meaningful impact is CuraCell’s work targeting so-called “cold tumors”- cancers that are resistant to current immunotherapies due to a lack of immune infiltration. These tumors, which include some of the deadliest solid cancers, have historically had no effective curative options. To address this challenge, CuraCell is developing novel T-cell therapies designed to penetrate and activate within these immunologically “cold” tumor environments.

Central to this approach is CytoPLY, CuraCell’s proprietary T-cell expansion and activation platform. CytoPLY enables the generation of highly potent, tumor-targeted T cells with enhanced functionality, addressing key biological barriers that have limited the success of T-cell therapies in solid oncology to date. Through this platform, CuraCell is advancing multiple therapeutic candidates with the potential to convert cold tumors into responsive tumors, extending the reach of T-cell therapy beyond today’s limitations.

Together, these efforts reflect CuraCell’s mission to push the frontier of oncology by delivering next-generation T-cell treatments for cancers that currently lack effective options.

How is your organisation collaborating to advance cancer awareness, prevention, or treatment?

At CuraCell, collaboration is central to advancing cancer awareness, prevention, and most importantly, next-generation treatments for patients with hard-to-treat solid tumors.

For the clinical translation of its T-cell therapy programs, CuraCell collaborates with Krankenhaus Nordwest Frankfurt (KNWH), which serves as a key clinical partner for Phase I/IIa studies. This collaboration enables alignment of therapies and programs with real-world clinical needs, accelerates patient access to innovative cellular therapies, and supports the generation of clinically meaningful evidence in solid tumor indications.

On the academic and R&D side, CuraCell works with leading European research institutions, including Uppsala University and Karolinska Institutet. These partnerships strengthen the scientific foundation and support translational research across immunology, cell therapy, and tumor biology.

In parallel, CuraCell is collaborating with ScaleReady on process development, enabling T-cell therapies to move efficiently from research into clinical and future commercial production.

By integrating clinical expertise at KNWH, academic excellence at Uppsala and Karolinska, and manufacturing enablement through ScaleReady, CuraCell is building a collaborative ecosystem that accelerates the development of scalable T-cell therapies for solid tumors with currently limited or no effective treatment options.